Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo khoa học: "Severe skin reaction secondary to concomitant radiotherapy plus cetuximab"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: "Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. | Radiation Oncology BioMed Central Short report Open Access Severe skin reaction secondary to concomitant radiotherapy plus cetuximab Bernhard Berger and Claus Belka Address Department of Radiation Oncology University of Tubingen Hoppe-Seyler-Str. 3 72076 Tubingen Germany Email Bernhard Berger - bernhard.berger@med.uni-tuebingen.de Claus Belka - claus.belka@med.uni-tuebingen.de Corresponding author Published 28 January 2008 Received 7 November 2007 Radiation Oncology 2008 3 5 doi 10.1186 1748-717X-3-5 Accepted 28 January 2008 This article is available from http www.ro-journal.com content 3 1 5 2008 Berger and Belka licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.Org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor EGFR is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor EGFRI cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study population several reports indicate a possible overlap between radiation dermatitis and the EGFRI-induced skin rash. We here present a case of severe skin reaction secondary to the addition of cetuximab to radiotherapy. Findings A 56-year-old woman with squamous cell cancer of the head and neck received primary chemoradiation at our institution. Due to thrombocytopenia chemotherapy had to be stopped early and was replaced by the EGFR inhibitor cetuximab. In a close temporal relationship to the first dose exacerbation of a pre-existing grade 1 radiation erythema occurred within the high-dose radiation portals. Clinically features of both the EGFRI-induced acne-like rash .